Related Experiment Video

Updated: Jul 17, 2026

Enabling High Grayscale Resolution Displays and Accurate Response Time Measurements on Conventional Computers
06:50

Enabling High Grayscale Resolution Displays and Accurate Response Time Measurements on Conventional Computers

Published on: February 29, 2012

Measuring response in a post-RECIST world: from black and white to shades of grey

Laura C Michaelis1, Mark J Ratain

  • 1Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, Illinois 60637, USA.

Nature Reviews. Cancer
|April 25, 2006
PubMed

Insights

The rapid advancement of cancer therapies necessitates new ways to measure drug effectiveness in early development. Traditional methods are inadequate, requiring more innovative trial designs for novel anticancer agents.

Area of Science:

  • Oncology
  • Drug Development
  • Clinical Trials

Background:

  • The rapid pace of therapeutic innovation in oncology challenges traditional methods for evaluating anticancer agent activity.
  • Current criteria for tumor response evaluation may be insufficient for assessing novel therapeutic agents.
  • There is a need to adapt early drug development strategies to the evolving landscape of cancer treatment.

Approach:

  • This analysis examines the historical context of current tumor response evaluation standards.
  • It explores the difficulties and pitfalls associated with using these traditional standards for newer anticancer agents.
  • The study advocates for revised outcome measurements and more imaginative early-phase trial designs.

Key Points:

  • Traditional endpoints for evaluating anticancer agent activity may no longer be adequate due to rapid therapeutic advancements.
  • The transition to new endpoints in early drug development faces significant challenges.
  • Existing criteria for tumor response evaluation present limitations when applied to novel anticancer agents.

Conclusions:

  • The current drug development environment demands different outcome measurements for anticancer agents.
  • More imaginative and rigorous early-phase trial designs are essential for accurately assessing novel therapies.
  • Adapting evaluation methods is crucial for effective oncology drug development.

More Related Videos

Determination of Photoreceptor Cell Spectral Sensitivity in an Insect Model from In Vivo Intracellular Recordings08:33

Determination of Photoreceptor Cell Spectral Sensitivity in an Insect Model from In Vivo Intracellular Recordings

Published on: February 26, 2016

Visualizing Visual Adaptation04:43

Visualizing Visual Adaptation

Published on: April 24, 2017

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Color Vision01:24

Color Vision

Color perception begins in the retina, the light-sensitive layer at the back of the eye. Two main theories explain how colors are seen: the trichromatic theory and the opponent-process theory. The trichromatic theory, proposed by Thomas Young in 1802 and extended by Hermann von Helmholtz in 1852, suggests that color vision is based on three types of cone receptors in the retina. These cones are sensitive to different but overlapping ranges of wavelengths corresponding to red, blue, and green.